(NASDAQ: BIVI) Biovie's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.
Biovie's earnings in 2026 is -$22,116,407.On average, 3 Wall Street analysts forecast BIVI's earnings for 2027 to be -$4,846,899, with the lowest BIVI earnings forecast at -$4,656,825, and the highest BIVI earnings forecast at -$4,989,455. On average, 3 Wall Street analysts forecast BIVI's earnings for 2028 to be -$4,385,290, with the lowest BIVI earnings forecast at -$4,213,318, and the highest BIVI earnings forecast at -$4,514,269.
In 2029, BIVI is forecast to generate -$4,231,420 in earnings, with the lowest earnings forecast at -$4,065,482 and the highest earnings forecast at -$4,355,873.